Search Within

Andrew D Seidman

Formats
  1. Journal Article (175)
  2. Meeting Abstract (123)
  3. Conference Paper (9)
  4. Correspondence (3)
  5. Review (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Editorial (1)
Groups
  1. Breast Medicine Service (318)
  2. Department of Medicine (318)
  3. Solid Tumor Oncology Division (318)
  4. Survivorship Research (158)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (116)
  6. Epidemiology and Biostatistics (84)

More Groups

People
  1. Clifford Hudis (116)
  2. Larry Norton (99)
  3. Teresa Gilewski (38)
  4. Monica Fornier (37)
  5. Gabriella D'Andrea-Carlino (36)
  6. Violante Currie (32)

More People

Years
  1. 2025 (3)
  2. 2024 (4)
  3. 2023 (10)
  4. 2022 (6)
  5. 2021 (9)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (83)
  2. Breast Cancer Research and Treatment (25)
  3. Cancer Research (23)
  4. Clinical Breast Cancer (19)
  5. Seminars in Oncology (16)
  6. Oncology (Norwalk) (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (84)
  2. Elsevier Inc. (55)
  3. Springer (40)
  4. American Association for Cancer Research (36)
  5. Oxford University Press (29)
  6. C M P Medica LLC * The Oncology Group (14)

More Publishers

Results (318)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Weekly (W) herceptin (H) and taxol (T) for metastatic breast cancer (MBC): Correlation of response rate to HER2 immunophenotype (immunohistochemistry (IHC)) and gene amplification (fluorescent in-situ hybridization (FISH))
    Meeting Abstract

    Fornier, M.; Seidman, A. D.; Esteva, F.; Tan, L.; Kaptain, S.; Bach, A.; Arroyo, C. D.; Hortobagyi, G.; Norton, L.; Hudis, C.
    European Journal of Cancer (2000)

    Fulltext@MSK | Save
  • Clinical-pathologic assessment of the clinical sensitivity to single agent taxane (T) therapy for metastatic breast cancer (MBC)
    Meeting Abstract

    Van Poznak, C.; Tan, L.; Panageas, K.; Arroyo, C.; Hudis, C.; Norton, L.; Seidman, A. D.
    Breast Cancer Research and Treatment (2000)

    Fulltext@MSK | Save
  • Commentary on 'Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer'
    Journal Article

    Seidman, A.
    Clinical Breast Cancer (2000)

    Fulltext@MSK | Save
  • Commentary on 'High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: Current status, future trends'
    Journal Article

    Seidman, A. D.
    Clinical Breast Cancer (2000)

    Fulltext@MSK | Save
  • Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer
    Journal Article

    Fornier, M.; Esteva, F. J.; Seidman, A. D.
    Seminars in Oncology (2000)

    Fulltext@MSK | Save
  • Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
    Journal Article

    Baselga, J.; Pfister, D.; Cooper, M. R.; Cohen, R.; Burtness, B.; Bos, M.; D'Andrea, G.; Seidman, A.; Norton, L.; Gunnett, K.; more...
    Journal of Clinical Oncology (2000)

    Fulltext@MSK | Save
  • An immunotherapeutic approach to treatment of breast cancer: Focus on trastuzumab plus paclitaxel
    Journal Article

    Gilewski, T.; Seidman, A.; Norton, L.; Hudis, C.
    Cancer Chemotherapy and Pharmacology (2000)

    Fulltext@MSK | Save
  • Phase II trial of weekly 1-hour taxol and herceptin for metastatic breast cancer: Toward further exploitation of proven synergistic antitumor activity
    Meeting Abstract

    Seidman, A. D.; Fornier, M.; Hudis, C.; Theodoulou, M.; Surbone, A.; Moynahan, M. E.; Currie, V.; Moasser, M.; Chin, J.; Bach, A.; more...
    Cancer Investigation (1999)

    Fulltext@MSK | Save
  • Herceptin in the treatment of advanced breast cancer
    Meeting Abstract

    Norton, L.; Baselga, J.; Seidman, A.; Hudis, C.; Theodoulou, M.
    Cancer Investigation (1999)

    Fulltext@MSK | Save
  • Preliminary results of a phase 1 study of a third-generation selective estrogen receptor modulator (SERM3, LY353381.HC1) in refractory, metastatic breast cancer
    Meeting Abstract

    Hudis, C.; Buzdar, A.; Munster, P.; Booser, D.; Seidman, A.; Theriault, R.; Moasser, M.; Frye, D.; Surbone, A.; Major, M.; more...
    Cancer Investigation (1999)

    Fulltext@MSK | Save